Suppr超能文献

囊性纤维化患者血浆中的肿瘤坏死因子α

Plasma tumour necrosis factor alpha in cystic fibrosis.

作者信息

Norman D, Elborn J S, Cordon S M, Rayner R J, Wiseman M S, Hiller E J, Shale D J

机构信息

Respiratory Medicine Unit, University of Nottingham.

出版信息

Thorax. 1991 Feb;46(2):91-5. doi: 10.1136/thx.46.2.91.

Abstract

Plasma tumour necrosis factor alpha (alpha) concentration is increased in acute Gram negative sepsis, but the effect of chronic infection on plasma concentrations is unknown. A study was carried out in patients with cystic fibrosis to determine the effect of chronic lung infection with Pseudomonas aeruginosa on the plasma concentration of tumour necrosis factor and two other indicators of the inflammatory response, circulating C reactive protein and neutrophil elastase-alpha 1 antiproteinase complex (elastase complex). The concentration of immunoreactive tumour necrosis factor in plasma was greater than the upper 95% confidence interval for healthy subjects (2.6 U/ml) on 129 out of 189 occasions in 14 patients observed for about a year. The increase in tumour necrosis factor was associated with increased circulating C reactive protein and elastase complex. Twelve patients with an exacerbation of respiratory symptoms were studied before and after two weeks' treatment with anti-pseudomonal antibiotics. All three indicators of the inflammatory response fell after treatment, though median tumour necrosis factor (4.8 U/ml) and elastase complex (0.41 microgram/ml) concentrations remained above the upper limits for healthy subjects. During a period of clinical stability plasma tumour necrosis factor was increased in 10 of the 12 patients, elastase complex was increased in 10 of the 12, and C reactive protein was increased in seven. Increased plasma immunoreactive tumour necrosis factor was a feature of the near continuous inflammatory response to chronic P aeruginosa infection in cystic fibrosis and may be a factor contributing to the progressive lung destruction seen in this disease.

摘要

急性革兰阴性菌败血症时血浆肿瘤坏死因子α(TNF-α)浓度会升高,但慢性感染对血浆浓度的影响尚不清楚。对囊性纤维化患者进行了一项研究,以确定铜绿假单胞菌慢性肺部感染对肿瘤坏死因子血浆浓度以及炎症反应的另外两个指标——循环C反应蛋白和中性粒细胞弹性蛋白酶-α1抗蛋白酶复合物(弹性蛋白酶复合物)的影响。在对14例患者进行了约一年的观察中,189次检测中有129次血浆中免疫反应性肿瘤坏死因子的浓度高于健康受试者的95%可信区间上限(2.6 U/ml)。肿瘤坏死因子的升高与循环C反应蛋白和弹性蛋白酶复合物的增加有关。对12例呼吸道症状加重的患者在使用抗假单胞菌抗生素治疗两周前后进行了研究。治疗后,炎症反应的所有三个指标均下降,尽管肿瘤坏死因子中位数(4.8 U/ml)和弹性蛋白酶复合物中位数(0.41μg/ml)浓度仍高于健康受试者的上限。在临床稳定期,12例患者中有10例血浆肿瘤坏死因子升高,12例中有10例弹性蛋白酶复合物升高,7例C反应蛋白升高。血浆免疫反应性肿瘤坏死因子升高是囊性纤维化患者对铜绿假单胞菌慢性感染近乎持续的炎症反应的一个特征,可能是导致该疾病中进行性肺破坏的一个因素。

相似文献

1
Plasma tumour necrosis factor alpha in cystic fibrosis.
Thorax. 1991 Feb;46(2):91-5. doi: 10.1136/thx.46.2.91.
3
Tumour necrosis factor-alpha, resting energy expenditure and cachexia in cystic fibrosis.
Clin Sci (Lond). 1993 Nov;85(5):563-8. doi: 10.1042/cs0850563.
4
Circulating immunoreactive interleukin-6 in cystic fibrosis.
Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1764-9. doi: 10.1164/ajrccm.157.6.9704086.
5
Inflammatory markers in cystic fibrosis.
Respir Med. 1991 Mar;85(2):139-45. doi: 10.1016/s0954-6111(06)80292-1.
6
Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa.
Eur Respir J. 2003 Sep;22(3):503-6. doi: 10.1183/09031936.03.00004503.
8
Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis.
Acta Paediatr. 1992 Mar;81(3):227-30. doi: 10.1111/j.1651-2227.1992.tb12209.x.

引用本文的文献

2
Systemic Inflammation and Oxidative Stress in Adults with Bronchiectasis: Association with Clinical and Functional Features.
Clinics (Sao Paulo). 2021 Apr 16;76:e2474. doi: 10.6061/clinics/2021/e2474. eCollection 2021.
3
Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.
Pediatr Pulmonol. 2017 Nov;52(S48):S21-S28. doi: 10.1002/ppul.23768. Epub 2017 Jul 17.
4
Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations.
PLoS One. 2017 Feb 8;12(2):e0171229. doi: 10.1371/journal.pone.0171229. eCollection 2017.
5
Novel end points for clinical trials in young children with cystic fibrosis.
Expert Rev Respir Med. 2013 Jun;7(3):231-43. doi: 10.1586/ers.13.25.
6
Potential of anti-inflammatory treatment for cystic fibrosis lung disease.
J Inflamm Res. 2010;3:61-74. doi: 10.2147/jir.s8875. Epub 2010 Aug 10.
8
Sputum biomarkers of inflammation in cystic fibrosis lung disease.
Proc Am Thorac Soc. 2007 Aug 1;4(4):406-17. doi: 10.1513/pats.200703-044BR.
10
Monitoring inflammation in CF. Cytokines.
Clin Rev Allergy Immunol. 2002 Aug;23(1):41-57. doi: 10.1385/CRIAI:23:1:041.

本文引用的文献

1
A rapid and sensitive solid-phase enzyme immunoassay for C-reactive protein.
J Immunol Methods. 1982;48(1):45-50. doi: 10.1016/0022-1759(82)90208-3.
2
Cystic fibrosis: a not-so-fatal disease.
Pediatr Clin North Am. 1974 Nov;21(4):935-50. doi: 10.1016/s0031-3955(16)33069-3.
4
Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis.
Am Rev Respir Dis. 1985 Sep;132(3):529-35. doi: 10.1164/arrd.1985.132.3.529.
7
Cytokines as inflammatory mediators.
Br Med Bull. 1987 Apr;43(2):350-70. doi: 10.1093/oxfordjournals.bmb.a072187.
9
Cytokine appearance in human endotoxemia and primate bacteremia.
Surg Gynecol Obstet. 1988 Feb;166(2):147-53.
10
The role of immune complexes in the pathogenesis of bacterial infections.
Annu Rev Microbiol. 1986;40:29-53. doi: 10.1146/annurev.mi.40.100186.000333.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验